ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDT
Company Participants
Adam Grossman – Co-Founder, President, CEO & Director
P. Terence Kohler – CFO & Treasurer
Conference Call Participants
Anthony Petrone – Mizuho Securities USA LLC, Research Division
Gary Nachman – Canaccord Genuity Corp., Research Division
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Presentation
Operator
Good afternoon, and welcome to the ADMA Biologics First Quarter 2026 Financial Results and Business Update Conference Call on Wednesday, May 6, 2026. [Operator Instructions] There will be a question-and-answer session to follow.
Please be advised that this call is being recorded at the company’s request and will be available on the company’s website approximately 2 hours following the end of the call.
At this time, I would like to introduce the company. Please go ahead.
Unknown Attendee
Welcome, everyone, and thank you for joining us this afternoon to discuss ADMA Biologics financial results for the first quarter of 2026 and recent corporate updates, I’m joined today by Adam Grossman, our President and Chief Executive Officer; Terry Kohler, Chief Financial Officer and Treasurer.
During today’s call, Adam will provide some introductory comments and provide an update on corporate progress, and Terry will provide an overview of the company’s first quarter 2026 financial results. Finally, Adam will then provide some brief summary remarks before opening the call up for questions. Earlier today, we issued a press release detailing the first quarter 2026 financial results and summarized certain achievements and recent corporate updates. The release is available on our website at www.admabiologics.com.
Before we begin our formal comments, I’ll remind you that we will be making forward-looking assertions during today’s call that represent the company’s intentions, expectations or beliefs concerning future events which constitute forward-looking statements for the purposes of the safe
